Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 4Recruiting 3Active not recruiting 3Withdrawn 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 333Neoplasms 221Prostatic Neoplasms 197Carcinoma, Non-Small-Cell Lung 156Lung Neoplasms 135Pancreatic Neoplasms 118Colorectal Neoplasms 103Neoplasm Metastasis 100Carcinoma, Hepatocellular 96Leukemia, Myeloid, Acute 94Multiple Myeloma 91Brain Neoplasms 89Lymphoma 86Head and Neck Neoplasms 76Melanoma 73Ovarian Neoplasms 72Leukemia 71Leukemia, Lymphocytic, Chronic, B-Cell 69Glioblastoma 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Colonic Neoplasms 61Recurrence 59Lymphoma, Non-Hodgkin 54Rectal Neoplasms 50Hematologic Neoplasms 50Lymphoma, Follicular 49Glioma 49Squamous Cell Carcinoma of Head and Neck 47Lymphoma, Large B-Cell, Diffuse 47Carcinoma, Renal Cell 47

Interventions

palbociclib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Carcinoma, Endometrioid × Clear all
NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

University of California, San Francisco

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

NCT01732432 2015-04-01

EAOC

University Hospital, Basel, Switzerland

Withdrawn

Endometriosis, Adenocarcinoma, Clear Cell, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡